Literature DB >> 26239284

Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer.

David Groheux1, Elif Hindié2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26239284     DOI： 10.1007/s00259-015-3144-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  14 in total

1.  Additional value of PET-CT in staging of clinical stage IIB and III breast cancer.

Authors:  Isabelle Segaert; Felix Mottaghy; Sarah Ceyssens; Walter De Wever; Sigrid Stroobants; Chantal Van Ongeval; Eric Van Limbergen; Hans Wildiers; Robert Paridaens; Ignace Vergote; Marie-Rose Christiaens; Patrick Neven
Journal:  Breast J       Date:  2010 Nov-Dec       Impact factor: 2.431

2.  ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

Authors:  Alexandre Cochet; Inna Dygai-Cochet; Jean-Marc Riedinger; Olivier Humbert; Alina Berriolo-Riedinger; Michel Toubeau; Séverine Guiu; Charles Coutant; Bruno Coudert; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-07       Impact factor: 9.236

3.  Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.

Authors:  David Groheux; Elif Hindié; Sylvie Giacchetti; Anne-Sophie Hamy; Frederique Berger; Pascal Merlet; Anne de Roquancourt; Patricia de Cremoux; Michel Marty; Mathieu Hatt; Marc Espié
Journal:  Eur J Cancer       Date:  2014-05-16       Impact factor: 9.162

4.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

5.  Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

Authors:  David Groheux; Mohamed Majdoub; Florent Tixier; Catherine Cheze Le Rest; Antoine Martineau; Pascal Merlet; Marc Espié; Anne de Roquancourt; Elif Hindié; Mathieu Hatt; Dimitris Visvikis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-04       Impact factor: 9.236

6.  Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.

Authors:  D Groheux; S Giacchetti; M Delord; A de Roquancourt; P Merlet; A S Hamy; M Espié; E Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-29       Impact factor: 9.236

7.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

8.  Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.

Authors:  Christopher C Riedl; Elina Slobod; Maxine Jochelson; Monica Morrow; Debra A Goldman; Mithat Gonen; Wolfgang A Weber; Gary A Ulaner
Journal:  J Nucl Med       Date:  2014-09-11       Impact factor: 10.057

9.  Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.

Authors:  Kenjiro Aogi; Takayuki Kadoya; Yoshifumi Sugawara; Sachiko Kiyoto; Hideo Shigematsu; Norio Masumoto; Morihito Okada
Journal:  Breast Cancer Res Treat       Date:  2015-02-20       Impact factor: 4.872

10.  HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.

Authors:  D Groheux; S Giacchetti; M Hatt; M Marty; L Vercellino; A de Roquancourt; C Cuvier; F Coussy; M Espié; E Hindié
Journal:  Br J Cancer       Date:  2013-08-13       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.